This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Makhteshim Agan Appoints Dr. Anders Harfstrand As Head Of Its European Operations

TEL-AVIV, Israel, Nov. 18, 2012 /PRNewswire/ --  The Makhteshim Agan Group ("MAI" or the "Company"), the world leader in branded off-patent crop protection solutions, today announced the appointment of Dr. Anders Harfstrand as President & Chief Executive Officer of its Europe Region. The appointment is effective as of January 1, 2013.

Dr. Harfstrand, who will be based in the Company's headquarters in Switzerland, has also been appointed a member of MAI's senior management team. In his new role, he will work closely with MAI's European Leadership Team, as well as promote cooperation between MAI's Europe Region and its other regions to better facilitate the Company's holistic business approach. He replaces erIgnacio Dominguez, that is taking over the position of the Company's Chief Commercial Officer and head of its Products & Marketing Division.

Dr. Harfstrand brings to MAI two decades of experience as a senior business executive at leading pharmaceutical companies. Most recently, he was President and CEO of Humabs Biomed SA, a Swiss-based company engaged in the discovery of human monoclonal antibodies and CEO of NITEC Pharma AG. Dr. Harfstrand was also the Senior Executive Vice President, Marketing and Sales in charge of Central and Eastern Europe, the Nordic, Asia, Latin America and Canada at Serono International SA. Prior to that, he held a number of executive positions at Pfizer, including Executive Vice President of Specialty Products and Business Development of Pfizer Japan, as well as Vice President of Pharmacia in charge of several of the global main therapy areas.

He is a member of the boards of public and private Swiss pharmaceutical companies, as well as the Chairman of Harfstrand Consulting Company. Dr. Harfstrand received his PhD in Medical Science and MD from Sweden's Karolinska Institute.  

Commenting on the appointment, Mr. Erez Vigodman , President and CEO of Makhteshim Agan, stated, "I am delighted to welcome Anders Harfstrand to MAI. Dr. Harfstrand is a strong business leader who brings to our company deep, hands-on managerial experience in the pharma industry, especially in strategic sales and marketing, business development and M&A. His broad skillset and knowledge of multi-cultural global organizations, such as ours, will be an important asset for MAI as we continue to expand our global and European operations. I look forward to working with Anders and am certain that MAI in general and our European region in particular, will benefit greatly from his extensive knowledge, experience skills and capabilities." 

About Makhteshim Agan Makhteshim Agan Industries Ltd. is a leading manufacturer and distributor worldwide of crop-protection solutions and the largest off-patent player in the industry. The Company supplies efficient solutions to farmers that assist them in combating disease and increasing yields. In 2011, the Company's revenues were over $2.69 billion, and it is ranked seventh in the world in the overall agro-chemicals industry. The Company is characterized by its know-how, high-level technological-chemical abilities, expertise in product registration, and observance of strict standards of environmental protection, stringent quality control and global marketing and distribution channels. For more information, visit us at www.ma-industries.com.

Contact: Rony Patishi-Chillim SVP of Global Corporate Communications Email: IR@ma-industries.com Phone: +972 73 232 1941

SOURCE Makhteshim Agan Industries Ltd.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs